IN2014CN04498A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04498A
IN2014CN04498A IN4498CHN2014A IN2014CN04498A IN 2014CN04498 A IN2014CN04498 A IN 2014CN04498A IN 4498CHN2014 A IN4498CHN2014 A IN 4498CHN2014A IN 2014CN04498 A IN2014CN04498 A IN 2014CN04498A
Authority
IN
India
Prior art keywords
domain
sequence
terminus
amino acid
protein
Prior art date
Application number
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Pawlak
Michal Szymanik
Anna Maria Pieczykolan
Bartlomiej Maciej Zerek
Piotr Rózga
Albert Robert Jaworski
Kaminska Malgorzata Izabela Teska
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of IN2014CN04498A publication Critical patent/IN2014CN04498A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN4498CHN2014 2011-11-28 2012-11-28 IN2014CN04498A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne
PCT/IB2012/056806 WO2013080147A2 (en) 2011-11-28 2012-11-28 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
IN2014CN04498A true IN2014CN04498A (pt) 2015-09-11

Family

ID=47561689

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4498CHN2014 IN2014CN04498A (pt) 2011-11-28 2012-11-28

Country Status (18)

Country Link
US (1) US20150044162A1 (pt)
EP (1) EP2785362A2 (pt)
JP (1) JP2015500228A (pt)
KR (1) KR20140097529A (pt)
CN (1) CN103974711A (pt)
AU (1) AU2012345494A1 (pt)
BR (1) BR112014012808A2 (pt)
CA (1) CA2856480A1 (pt)
EA (1) EA201491049A1 (pt)
HK (1) HK1201727A1 (pt)
IL (1) IL232743A0 (pt)
IN (1) IN2014CN04498A (pt)
MX (1) MX2014006369A (pt)
PH (1) PH12014501083A1 (pt)
PL (1) PL397167A1 (pt)
SG (1) SG11201402312WA (pt)
WO (1) WO2013080147A2 (pt)
ZA (1) ZA201404667B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2970487T (pt) 2013-03-12 2020-06-17 Molecular Templates Inc Proteínas citotóxicas compreendendo regiões de ligação de direcionamento para células e regiões de subunidades de toxina a shiga para a morte seletiva de tipos específicos de células
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
AU2015209063C1 (en) 2014-01-27 2020-06-25 Molecular Templates, Inc. MHC class I epitope delivering polypeptides
EP3825327A1 (en) * 2014-03-11 2021-05-26 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2919749T3 (es) 2014-06-11 2022-07-28 Molecular Templates Inc Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
AU2016215205B2 (en) 2015-02-05 2021-10-21 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
LT3303373T (lt) * 2015-05-30 2020-07-10 Molecular Templates, Inc. Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
CN106380521B (zh) 2015-07-02 2020-12-29 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
KR101732126B1 (ko) 2015-11-05 2017-05-02 한국생명공학연구원 췌장암 치료용 융합 단백질 및 이의 용도
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
IL293710B2 (en) 2016-12-07 2024-10-01 Molecular Templates Inc Shiga toxin A subunit activator polypeptides, Shiga toxin activator scaffolds and cell-targeting molecules for site-specific conjugation
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
US20200024312A1 (en) 2017-01-25 2020-01-23 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
CN112105631A (zh) * 2018-03-06 2020-12-18 约翰霍普金斯大学 Treg耗尽和检查点抑制剂的组合
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
US20220211872A1 (en) * 2019-05-15 2022-07-07 Universidad De Granada Gene therapy with the genes hokd and ldrb for cancer treatments
CN113354738B (zh) * 2020-03-05 2022-09-09 绍兴德方华生物技术有限公司 融合毒素VEGF165b/mGEL及其编码基因与应用
WO2022038152A1 (en) * 2020-08-17 2022-02-24 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase
CN114681599B (zh) * 2020-12-31 2024-07-02 中国科学院上海药物研究所 一种阳离子脂质体疫苗及其制备方法和用途
CN117384859B (zh) * 2023-12-13 2024-03-22 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
AU2001238501A1 (en) 2000-02-16 2001-08-27 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
CN1257187C (zh) * 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
JP4688678B2 (ja) 2003-11-03 2011-05-25 北京沙東生物技術有限公司 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用
US7252993B2 (en) 2004-03-12 2007-08-07 Battelle Energy Alliance, Llc Plasmids encoding therapeutic agents
US8907060B2 (en) 2005-07-29 2014-12-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mutated Pseudomonas exotoxins with reduced antigenicity
ATE533058T1 (de) 2005-08-16 2011-11-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
US20100215670A1 (en) 2006-10-30 2010-08-26 Jeannick Cizeau Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers
EP2097529A4 (en) 2006-12-29 2010-03-24 Osprey Pharmaceuticals Usa Inc METHOD FOR SELECTION AND PRODUCTION OF MODIFIED TOXINS, MODIFIED TOXINE CONJUGATES AND USES THEREOF
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
PT2252627T (pt) * 2008-01-24 2017-07-24 Esperance Pharmaceuticals Constructos de fusão de domínio lítico e métodos para produzir e utilizar os mesmos
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer
SG191698A1 (en) * 2008-06-30 2013-07-31 Univ Pennsylvania Fn14/trail fusion proteins

Also Published As

Publication number Publication date
ZA201404667B (en) 2015-09-30
HK1201727A1 (en) 2015-09-11
IL232743A0 (en) 2014-07-31
PL397167A1 (pl) 2013-06-10
CA2856480A1 (en) 2013-06-06
US20150044162A1 (en) 2015-02-12
WO2013080147A2 (en) 2013-06-06
AU2012345494A1 (en) 2014-07-10
WO2013080147A3 (en) 2014-02-13
CN103974711A (zh) 2014-08-06
EA201491049A1 (ru) 2014-10-30
PH12014501083A1 (en) 2014-08-04
MX2014006369A (es) 2014-07-09
SG11201402312WA (en) 2014-06-27
JP2015500228A (ja) 2015-01-05
EP2785362A2 (en) 2014-10-08
KR20140097529A (ko) 2014-08-06
BR112014012808A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
IN2014CN04498A (pt)
MX337436B (es) Proteina de funsion anticancer.
MX339203B (es) Proteina de fusion anticancer.
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
IN2014KN01715A (pt)
MX2014008028A (es) Proteina de fusion anticancerigena.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
EA201990298A1 (ru) Способы и композиции для лечения рака
WO2012143477A3 (en) Anticancer fusion protein
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
MX2013003168A (es) Anticuerpo contra ephrin b2 y su uso.
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
PH12014502198A1 (en) Osteoprotegerin derived composition and use thereof
GB201019467D0 (en) Therapeutic agent
UA108911C2 (xx) Протираковий злитий протеїн
WO2013052168A3 (en) Detection aib1-delta 4 protein
TH139454A (th) การใช้แหล่ง l3และ/หรือ l5 ในฐานะเป็นวัคซีน หรือในเชิงวินิจฉัยสำหรับโรคปรสิต
TH159052A (th) ฟิวชั่นโปรตีนต้านมะเร็ง (Anticancer fusion protein)